质粒
同源重组
分子生物学
生物
绿色荧光蛋白
重组DNA
穿梭机载体
转染
FLP-FRT重组
Cre重组酶
体外重组
重组酶
载体(分子生物学)
基因
遗传重组
重组
遗传学
分子克隆
转基因
肽序列
转基因小鼠
出处
期刊:Chinese journal of microbiology and immunology
[Chinese Medical Association]
日期:2019-09-30
卷期号:39 (9): 645-651
标识
DOI:10.3760/cma.j.issn.0254-5101.2019.09.001
摘要
Objective
To rapidly and efficiently construct a replication-competent human recombinant adenovirus type 14 vector expressing enhanced green fluorescence protein (rAd14-EGFP) using in vitro homologous recombination.
Methods
The skeleton plasmid pBRAd14 was constructed using homologous recombination in Escherichia coli (E.coli) BJ5183 competent cells. The plamid was linearized and transfected into AD293 cells to rescue Ad14. Exnase, a recombinase, was used to construct the shuttle plasmid pSK14-EGFP in vitro using homologous recombination among four fragments. The overlapping sequence was 15-20 bp. Three exogenous fragments generated with PCR including Ad14 E3L fragment, EGFP gene and Ad14 E3R fragment were cloned into the plasmid pBluescript Ⅱ SK(-) simultaneously. Recombinant plasmid pBRAd14-EGFP was constructed by in vitro homologous recombination between 27 kb fragment of plasmid pBRAd14 obtained through double digestion and Ad14 E3L-EGFP-Ad14 E3R fragment amplified by PCR using the shuttle plasmid pSK14-EGFP as template. The plasmid pBRAd14-EGFP was linearized and transfected into cells to obtain the viral vector rAd14-EGFP, which was then used to immunize mice to detect the induced immune responses.
Results
A replication-competent E3-deleted adenovirus vector rAd14-EGFP expressing EGFP was successfully constructed. Intracellular proliferation properties and immunogenicity of the vector were no significantly differences compared with those of Ad14.
Conclusions
In vitro homologous recombination using the commercial recombinase Exnase can be a rapid, efficient and accurate method to construct adenoviral vector.
Key words:
Human adenovirus type 14; Recombinase Exnase; In vitro homologous recombination; Adenovirus vector
科研通智能强力驱动
Strongly Powered by AbleSci AI